☆ 4.7 Article

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Anne Emmanuelle Berger et al.

Summary: This study evaluated the application performance of a new chemiluminescent instrument (i-TRACK10(R)) in clinical decision-making. The results showed satisfactory intra- and inter-run performances of i-TRACK10(R) and generally comparable results to manual or automated ELISA. However, due to differences in anti-drug antibodies, it is recommended to use the same assay in the long-term follow-up of patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial

Silje Watterdal Syversen et al.

Summary: This study demonstrates that proactive therapeutic drug monitoring (TDM) is more effective than standard therapy in maintaining disease control and preventing disease worsening among patients with immune-mediated inflammatory diseases undergoing maintenance therapy with infliximab. Further research is needed to compare proactive TDM with reactive TDM and evaluate the cost-effectiveness of this approach.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics

Dan-in Jang et al.

Summary: TNF-α was originally identified as a factor causing tumor necrosis but has also been recognized as a pathological component of autoimmune diseases. Its signaling pathways play important roles in cellular responses, and inappropriate activation can lead to chronic inflammation and autoimmune diseases. TNF-α inhibitors have been developed as effective therapeutic tools for various autoimmune diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

David Ternant et al.

Summary: This study provided an in-depth description of infliximab target-mediated pharmacokinetics in IBD patients, using a two-compartment model with double TMDD. The model showed differences in target-mediated parameters and complex elimination rates between central and peripheral compartments, which could be useful for improving model-based therapeutic drug monitoring of infliximab in IBD patients.

PHARMACEUTICS (2021)

添加到收藏夹

Article Chemistry, Analytical

Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits

Emilio J. Laserna-Mendieta et al.

Summary: The study evaluated a new rapid quantitative method, Quantum Blue, for determining anti-ADL and anti-IFX antibodies, comparing it with two established ELISA kits. While QB anti-ADL showed similar performance to ELISA kits, QB anti-IFX needs further improvements for reliable antibody detection.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

Adam S. Cheifetz et al.

Summary: This study utilized a modified Delphi method to develop a consensus statement regarding the clinical utility of TDM for biologics in IBD, focusing on both reactive and proactive TDM. The results suggest the importance of using reactive TDM to enhance the efficacy of biologics, as well as the recommendation for regular proactive TDM during maintenance therapy.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Review Biochemical Research Methods

Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology

Merel van Nuland et al.

BIOMEDICAL CHROMATOGRAPHY (2020)

添加到收藏夹

Review Immunology

Immunogenicity of TNF-Inhibitors

Sadaf Atiqi et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Medical Laboratory Technology

A Comparative Evaluation of Four Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies.

Melissa Joyce Sam et al.

THERAPEUTIC DRUG MONITORING (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

Christian Maaser et al.

JOURNAL OF CROHNS & COLITIS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Nicholas A. Kennedy et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Christopher Andrew Lamb et al.

GUT (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review

Laura Martelli et al.

JOURNAL OF GASTROENTEROLOGY (2017)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Joseph D. Feuerstein et al.

GASTROENTEROLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease

Orlaith B. Kelly et al.

INFLAMMATORY BOWEL DISEASES (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Assays for measurement of TNF antagonists in practice

Niels Vande Casteele

FRONTLINE GASTROENTEROLOGY (2017)

添加到收藏夹

Review Rheumatology

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

George D. Kalliolias et al.

NATURE REVIEWS RHEUMATOLOGY (2016)

添加到收藏夹

Article Pathology

Comparison of infliximab drug measurement across three commercially available ELISA kits

Monique Wei Meng Lee et al.

PATHOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission

Aurelien Amiot et al.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2016)

添加到收藏夹

Review Oncology

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

Sarah S. Thomas et al.

BIODRUGS (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

Henit Yanai et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt et al.

GUT (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.